A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.
Gil AwadaYanina Jeanne Leona JansenJulia Katharina SchwarzeJens TijtgatLennert HellinckxOdrade GondrySim VermeulenSarah WarrenKelly SchatsPieter-Jan van DamMark KockxMarleen KeyaertsHendrik EveraertTeofila SeremetAnne RogiersBart NeynsPublished in: Cancers (2021)
Multiple baseline variables correlate with survival on pembrolizumab. TMTV is a more comprehensive baseline biomarker than CRP, LDH, or ALC in predicting the futility of pembrolizumab.